Clinical Trials Logo
  1. Home
  2. Body Dysmorphic Disorder
  3. NCT00265109

Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder

Body Dysmorphic Disorder Clinical Trial

Official title:
Open-Label Study of Levetiracetam in Body Dysmorphic Disorder

Clinical Trial Summary

The purpose of this study is to assess the usefulness of a medication (Levetiracetam) for people with body dysmorphic disorder.

Clinical Trial Description

Body dysmorphic disorder (BDD), a perceived defect in appearance (e.g., a "large" nose or facial "scarring"), is a relatively common disorder that causes marked distress and impairment in functioning. Recent data suggests that adults with BDD may respond to serotonin reuptake inhibitors (SRIs); however, response to SRIs is often only partial. About one third of patients do not respond to an SRI. Furthermore, patients may stop taking SRIs because of side effects (e.g., sexual side effects). For these reasons, additional monotherapy and SRI augmentation strategies are greatly needed.

Levetiracetam is primarily used as an antiseizure medication and has a wider safety margin than other antiepileptics. Preliminary scientific studies may suggest that it may be helpful for certain psychiatric symptoms and disorders. In the present study we propose to obtain pilot data on 1) levetiracetam monotherapy and 2) levetiracetam augmentation of SRIs in patients with BDD. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00265109
Study type Interventional
Source Butler Hospital
Contact
Status Completed
Phase Phase 4
Start date December 2004
Completion date January 2008
View Details
See also
  Status Clinical Trial Phase
Completed NCT02635152 - Interpretation Bias Modification for Body Dysmorphic Disorder N/A
Completed NCT03673046 - Waitlist-Control Trial of Smartphone Cognitive Behavioral Therapy (CBT) for Body Dysmorphic Disorder (BDD) N/A
Recruiting NCT05402475 - Online Cognitive Behavioural Therapy Intervention for Body Dysmorphic Disorder N/A
Withdrawn NCT02843451 - Milk Thistle in Body Dysmorphic Disorder Phase 2
Completed NCT02010619 - Internet Delivered CBT for Body Dysmorphic Disorder N/A
Completed NCT00842309 - D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder Early Phase 1
Completed NCT00245635 - Fluoxetine in Pediatric Body Dysmorphic Disorder Phase 4
Completed NCT02808702 - Brain Correlates of Self-Focused Processing N/A
Completed NCT01002326 - Cognitive-Behavioral Therapy for Pediatric Body Dysmorphic Disorder N/A
Active, not recruiting NCT01075672 - Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals N/A
Completed NCT02671266 - Oxytocin Administration in BDD and OCD Phase 2
Completed NCT01038128 - An Open Label Trial of Memantine in the Treatment of Bulimia Nervosa and Body Dysmorphic Disorder N/A
Completed NCT01398865 - Escitalopram Neuroimaging Supplement N/A
Recruiting NCT04373629 - Perceptual Abnormalities and Their Malleability in BDD N/A
Completed NCT01453439 - Cognitive-Behavioral Therapy and Supportive Psychotherapy for Body Dysmorphic Disorder N/A
Completed NCT00871143 - Cognitive Behaviour Therapy (CBT) for Body Dysmorphic Disorder (BDD) N/A
Completed NCT00106223 - Treatment Study Investigating New Cognitive Behavioral Therapy Treatment Manual for Body Dysmorphic Disorder N/A
Active, not recruiting NCT00211809 - CBT as an Adjunct to SRIs in the Treatment of BDD Phase 4